The potential benefits of DepoFoam® have attracted partners pursuing reformulations of product candidates with significant market potential. We are developing new formulations of traditional small molecule and biologic therapies to build a pipeline of commercial opportunities for proprietary pursuit, as well as for out-licensing. For partners, this approach may provide a low risk clinical and regulatory development opportunity.
- We have created formulations for six of the current top selling biologics including EPO, G-CSF, hGH, IFN-α, FSH, and several undisclosed molecules.
- We have developed feasibility data on a number of products, including a project to reengineer the delivery of methotrexate, a disease-modifying antirheumatic drug, to extend its delivery over several days while minimizing side effects.
- Partnering opportunities exist for EXPAREL® (bupivacaine liposome injectable suspension).
- Pacira leases and operates cGMP clinical and commercial manufacturing facilities in San Diego that are fully compliant with all major regulatory authorities. Pacira has the capability to manufacture DepoFoam-based medications for its acute care customers, partners, and its pipeline products.
To inquire how our DepoFoam technology may enhance your product needs or products that are available for out-licensing, please contact our Business Development team at email@example.com.
Download Poster Sustained Release Multivesicular Liposomal (DepoFoam) Formulation of IFN-α2b that provides Sustained Plasma IFN-α2b levels for Seven Days